Sign in or create an account to add this stock to your watchlist.
About United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292
Debt
Debt-to-Equity Ratio0.11
Current Ratio5.13
Quick Ratio4.81
Price-To-Earnings
Trailing P/E Ratio8.19
Forward P/E Ratio7.94
P/E Growth26.49
Sales & Book Value
Annual Sales$1.73 billion
Price / Sales2.61
Cash Flow$12.0325 per share
Price / Cash8.61
Book Value$54.41 per share
Price / Book1.90
Profitability
EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Net Margins27.74%
Return on Equity26.68%
Return on Assets19.25%
Miscellaneous
Employees800
Outstanding Shares43,540,000
United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions
What is United Therapeutics' stock symbol?
United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."
How will United Therapeutics' stock buyback program work?
United Therapeutics declared that its board has approved a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its shares are undervalued.
How were United Therapeutics' earnings last quarter?
United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, May, 2nd. The biotechnology company reported $5.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.62 by $1.95. The biotechnology company had revenue of $389.20 million for the quarter, compared to analyst estimates of $393.96 million. United Therapeutics had a net margin of 27.74% and a return on equity of 26.68%. The business's revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.61 EPS. View United Therapeutics' Earnings History.
When is United Therapeutics' next earnings date?
What price target have analysts set for UTHR?
8 brokers have issued 12-month price targets for United Therapeutics' shares. Their predictions range from $95.00 to $232.00. On average, they expect United Therapeutics' share price to reach $130.75 in the next twelve months. View Analyst Ratings for United Therapeutics.
Who are some of United Therapeutics' key competitors?
Some companies that are related to United Therapeutics include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Sarepta Therapeutics (SRPT).
Who are United Therapeutics' key executives?
United Therapeutics' management team includes the folowing people:
- Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
- Mr. Michael I. Benkowitz, Pres & COO (Age 46)
- Mr. James C. Edgemond, CFO & Treasurer (Age 50)
- Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Kevin Gray, Sr. VP of Strategic Operations & Logistics
Has United Therapeutics been receiving favorable news coverage?
News headlines about UTHR stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. United Therapeutics earned a media sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are United Therapeutics' major shareholders?
United Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.28%), Palo Alto Investors LP (3.73%), Old Mutual Global Investors UK Ltd. (2.21%), Dimensional Fund Advisors LP (2.20%), FIL Ltd (1.48%) and Thompson Siegel & Walmsley LLC (1.25%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.
Which institutional investors are selling United Therapeutics stock?
UTHR stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Wells Fargo & Company MN, Royal Bank of Canada, Millennium Management LLC, BNP Paribas Arbitrage SA, Thompson Siegel & Walmsley LLC, Swiss National Bank and State of Tennessee Treasury Department. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.
Which institutional investors are buying United Therapeutics stock?
UTHR stock was acquired by a variety of institutional investors in the last quarter, including LSV Asset Management, BlackRock Inc., Mackay Shields LLC, Prudential Financial Inc., Robeco Institutional Asset Management B.V., UBS Group AG, Senzar Asset Management LLC and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for United Therapeutics.
How do I buy shares of United Therapeutics?
Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is United Therapeutics' stock price today?
One share of UTHR stock can currently be purchased for approximately $103.60.
How big of a company is United Therapeutics?
United Therapeutics has a market capitalization of $4.51 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.
How can I contact United Therapeutics?
United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]
MarketBeat Community Rating for United Therapeutics (UTHR)
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
United Therapeutics (NASDAQ:UTHR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for United Therapeutics in the last 12 months. Their average twelve-month price target is $130.75, suggesting that the stock has a possible upside of 26.21%. The high price target for UTHR is $232.00 and the low price target for UTHR is $95.00. There are currently 3 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 1.88 | 1.88 | 1.78 | 1.83 |
| Ratings Breakdown: | 3 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 4 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 4 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $130.75 | $133.3750 | $132.4444 | $132.8182 |
| Price Target Upside: | 26.21% upside | 24.16% upside | 8.41% upside | 11.52% upside |
United Therapeutics (NASDAQ:UTHR) Consensus Price Target History
United Therapeutics (NASDAQ:UTHR) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
United Therapeutics (NASDAQ:UTHR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
United Therapeutics (NASDAQ UTHR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 99.18%
United Therapeutics (NASDAQ UTHR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Martine A Rothblatt | CEO | Sell | 21,513 | $110.88 | $2,385,361.44 | 21,653 |  |
| 4/5/2018 | Martine A Rothblatt | CEO | Sell | 21,512 | $114.30 | $2,458,821.60 | 21,652 | |
| 4/3/2018 | Martine A Rothblatt | CEO | Sell | 22,059 | $114.44 | $2,524,431.96 | 687 | |
| 3/29/2018 | Martine A Rothblatt | CEO | Sell | 43,024 | $111.14 | $4,781,687.36 | 21,652 | |
| 3/22/2018 | Martine A Rothblatt | CEO | Sell | 1,100 | $110.01 | $121,011.00 | 1,240 | |
| 3/20/2018 | Martine A Rothblatt | CEO | Sell | 301 | $110.48 | $33,254.48 | 21,652 | |
| 3/16/2018 | Martine A Rothblatt | CEO | Sell | 43,025 | $111.11 | $4,780,507.75 | 21,652 | |
| 3/14/2018 | Martine A Rothblatt | CEO | Sell | 21,512 | $112.55 | $2,421,175.60 | 21,652 | |
| 12/8/2017 | Martine A Rothblatt | CEO | Sell | 1 | $136.16 | $136.16 | 141 | |
| 12/7/2017 | Christopher Causey | Director | Sell | 580 | $134.72 | $78,137.60 | 1,555 | |
| 11/30/2017 | Martine A Rothblatt | CEO | Sell | 1,241 | $128.95 | $160,026.95 | | |
| 11/24/2017 | Martine A Rothblatt | CEO | Sell | 1,253 | $124.07 | $155,459.71 | | |
| 11/16/2017 | Martine A Rothblatt | CEO | Sell | 7,061 | $121.12 | $855,228.32 | | |
| 11/9/2017 | Martine A Rothblatt | CEO | Sell | 1,260 | $121.46 | $153,039.60 | 1,400 | |
| 11/6/2017 | Christopher Causey | Director | Sell | 580 | $122.00 | $70,760.00 | 2,135 | |
| 11/2/2017 | Martine A Rothblatt | CEO | Sell | 1,269 | $118.04 | $149,792.76 | 1,409 | |
| 10/26/2017 | Martine A Rothblatt | CEO | Sell | 1,263 | $120.38 | $152,039.94 | 1,403 | |
| 10/19/2017 | Martine A Rothblatt | CEO | Sell | 1,265 | $119.38 | $151,015.70 | 1,405 | |
| 10/12/2017 | Martine A Rothblatt | CEO | Sell | 1,263 | $120.20 | $151,812.60 | | |
| 10/5/2017 | Christopher Causey | Director | Sell | 580 | $122.00 | $70,760.00 | | |
| 10/5/2017 | Martine A Rothblatt | CEO | Sell | 1,256 | $122.98 | $154,462.88 | | |
| 9/28/2017 | Martine A Rothblatt | CEO | Sell | 1,265 | $119.70 | $151,420.50 | 2,334 | |
| 9/21/2017 | Martine A Rothblatt | CEO | Sell | 1,274 | $116.07 | $147,873.18 | 2,343 | |
| 9/14/2017 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.08 | $153,576.64 | 2,327 | |
| 9/7/2017 | Christopher Causey | Director | Sell | 580 | $134.48 | $77,998.40 | 3,295 | |
| 9/7/2017 | Martine A Rothblatt | CEO | Sell | 1,232 | $133.32 | $164,250.24 | 2,301 | |
| 8/31/2017 | Martine A Rothblatt | CEO | Sell | 1,235 | $130.49 | $161,155.15 | 2,304 | |
| 8/24/2017 | Martine A Rothblatt | CEO | Sell | 1,238 | $130.65 | $161,744.70 | 2,307 | |
| 8/17/2017 | Martine A Rothblatt | CEO | Sell | 1,235 | $131.95 | $162,958.25 | 2,304 | |
| 8/10/2017 | Martine A Rothblatt | CEO | Sell | 2,176 | $127.11 | $276,591.36 | 3,245 | |
| 8/3/2017 | Martine A Rothblatt | CEO | Sell | 1,248 | $126.41 | $157,759.68 | 2,317 | |
| 7/27/2017 | Martine A Rothblatt | CEO | Sell | 1,247 | $126.40 | $157,620.80 | 2,316 | |
| 7/20/2017 | Martine A Rothblatt | CEO | Sell | 1,236 | $131.62 | $162,682.32 | 1,376 | |
| 7/13/2017 | Martine A Rothblatt | CEO | Sell | 1,238 | $130.44 | $161,484.72 | 1,378 | |
| 7/6/2017 | Christopher Causey | Director | Sell | 590 | $132.61 | $78,239.90 | 3,875 | |
| 7/6/2017 | Martine A Rothblatt | CEO | Sell | 1,234 | $132.29 | $163,245.86 | 1,374 | |
| 7/5/2017 | Richard Giltner | Director | Sell | 3,490 | $131.12 | $457,608.80 | | |
| 6/29/2017 | Martine A Rothblatt | CEO | Sell | 1,237 | $130.92 | $161,948.04 | 1,377 | |
| 6/23/2017 | Raymond Dwek | Director | Sell | 3,490 | $131.71 | $459,667.90 | | |
| 6/22/2017 | Martine A Rothblatt | CEO | Sell | 1,234 | $132.32 | $163,282.88 | 1,374 | |
| 6/15/2017 | Martine A Rothblatt | CEO | Sell | 1,238 | $130.20 | $161,187.60 | 1,378 | |
| 6/8/2017 | Martine A Rothblatt | CEO | Sell | 1,240 | $129.60 | $160,704.00 | 1,380 | |
| 6/1/2017 | Martine A Rothblatt | CEO | Sell | 1,251 | $125.02 | $156,400.02 | 1,391 | |
| 5/25/2017 | Martine A Rothblatt | CEO | Sell | 1,265 | $119.40 | $151,041.00 | 1,405 | |
| 5/18/2017 | Martine A Rothblatt | CEO | Sell | 1,261 | $120.72 | $152,227.92 | 1,401 | |
| 5/11/2017 | Martine A Rothblatt | CEO | Sell | 1,259 | $122.00 | $153,598.00 | 1,399 | |
| 5/4/2017 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.24 | $153,777.92 | 1,398 | |
| 4/27/2017 | Martine A Rothblatt | CEO | Sell | 1,262 | $120.78 | $152,424.36 | 1,402 | |
| 4/20/2017 | Martine A Rothblatt | CEO | Sell | 1,260 | $121.14 | $152,636.40 | 1,400 | |
| 4/13/2017 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.12 | $153,626.96 | 1,398 | |
| 4/6/2017 | Martine A Rothblatt | CEO | Sell | 1,257 | $122.39 | $153,844.23 | 1,397 | |
| 3/30/2017 | Martine A Rothblatt | CEO | Sell | 1,230 | $134.56 | $165,508.80 | 1,370 | |
| 3/23/2017 | Martine A Rothblatt | CEO | Sell | 1,219 | $139.33 | $169,843.27 | 1,359 | |
| 3/22/2017 | Tommy G Thompson | Director | Sell | 2,000 | $139.37 | $278,740.00 | 2,000 | |
| 3/16/2017 | Martine A Rothblatt | CEO | Sell | 1,218 | $140.16 | $170,714.88 | 1,358 | |
| 3/9/2017 | Martine A Rothblatt | CEO | Sell | 1,206 | $146.72 | $176,944.32 | 1,346 | |
| 3/2/2017 | Martine A Rothblatt | CEO | Sell | 1,203 | $148.49 | $178,633.47 | 1,343 | |
| 2/23/2017 | Martine A Rothblatt | CEO | Sell | 1,208 | $145.16 | $175,353.28 | 1,348 | |
| 2/16/2017 | Martine A Rothblatt | CEO | Sell | 1,173 | $167.92 | $196,970.16 | 1,313 | |
| 1/12/2017 | Christopher Patusky | Director | Sell | 5,000 | $141.99 | $709,950.00 | 5,000 | |
| 1/12/2017 | Martine A Rothblatt | CEO | Sell | 1,214 | $142.37 | $172,837.18 | 1,354 | |
| 1/5/2017 | Martine A Rothblatt | CEO | Sell | 1,208 | $145.73 | $176,041.84 | 1,348 | |
| 12/29/2016 | Martine A Rothblatt | CEO | Sell | 1,211 | $143.63 | $173,935.93 | 1,351 | |
| 12/22/2016 | Martine A Rothblatt | CEO | Sell | 1,218 | $140.23 | $170,800.14 | 1,358 | |
| 12/15/2016 | Martine A Rothblatt | CEO | Sell | 1,212 | $143.11 | $173,449.32 | 1,352 | |
| 12/8/2016 | Martine A Rothblatt | CEO | Sell | 1,236 | $131.78 | $162,880.08 | 1,376 | |
| 12/6/2016 | Richard Giltner | Director | Sell | 5,000 | $133.37 | $666,850.00 | 5,000 | |
| 12/1/2016 | Martine A Rothblatt | CEO | Sell | 1,246 | $126.86 | $158,067.56 | 1,386 | |
| 11/25/2016 | Martine A Rothblatt | CEO | Sell | 1,233 | $132.81 | $163,754.73 | 1,373 | |
| 11/17/2016 | Martine A Rothblatt | CEO | Sell | 1,232 | $132.94 | $163,782.08 | 1,372 | |
| 11/10/2016 | Christopher Patusky | Director | Sell | 5,000 | $131.42 | $657,100.00 | 5,000 | |
| 11/10/2016 | Martine A Rothblatt | CEO | Sell | 1,240 | $129.82 | $160,976.80 | 1,380 | |
| 11/3/2016 | Martine A Rothblatt | CEO | Sell | 1,272 | $116.94 | $148,747.68 | 1,412 | |
| 10/27/2016 | Martine A Rothblatt | CEO | Sell | 1,272 | $117.06 | $148,900.32 | 1,412 | |
| 10/20/2016 | Martine A Rothblatt | CEO | Sell | 1,282 | $113.30 | $145,250.60 | 1,422 | |
| 10/13/2016 | Martine A Rothblatt | CEO | Sell | 1,269 | $117.99 | $149,729.31 | 1,409 | |
| 10/6/2016 | Martine A Rothblatt | CEO | Sell | 1,260 | $121.17 | $152,674.20 | 1,400 | |
| 9/29/2016 | Martine A Rothblatt | CEO | Sell | 1,272 | $116.94 | $148,747.68 | 1,412 | |
| 9/26/2016 | Tommy G Thompson | Director | Sell | 1,291 | $125.57 | $162,110.87 | 1,291 | |
| 9/22/2016 | Martine A Rothblatt | CEO | Sell | 1,249 | $125.87 | $157,211.63 | 1,389 | |
| 9/15/2016 | Martine A Rothblatt | CEO | Sell | 1,258 | $122.34 | $153,903.72 | 1,398 | |
| 9/8/2016 | Martine A Rothblatt | CEO | Sell | 1,254 | $123.44 | $154,793.76 | 1,394 | |
| 9/1/2016 | Christopher Patusky | Director | Sell | 5,000 | $122.73 | $613,650.00 | 5,000 | |
| 9/1/2016 | Martine A Rothblatt | CEO | Sell | 1,257 | $122.81 | $154,372.17 | 1,397 | |
| 8/25/2016 | Martine A Rothblatt | CEO | Sell | 1,250 | $125.29 | $156,612.50 | 1,390 | |
| 8/18/2016 | Martine A Rothblatt | CEO | Sell | 1,249 | $125.88 | $157,224.12 | 1,389 | |
| 8/11/2016 | Martine A Rothblatt | CEO | Sell | 1,253 | $124.09 | $155,484.77 | 1,393 | |
| 8/4/2016 | Martine A Rothblatt | CEO | Sell | 1,249 | $125.78 | $157,099.22 | 1,389 | |
| 7/28/2016 | Martine A Rothblatt | CEO | Sell | 1,271 | $117.05 | $148,770.55 | 1,411 | |
| 7/21/2016 | Martine A Rothblatt | CEO | Sell | 1,284 | $112.77 | $144,796.68 | 1,424 | |
| 7/14/2016 | Martine A Rothblatt | CEO | Sell | 1,292 | $110.05 | $142,184.60 | 1,432 | |
| 7/7/2016 | Martine A Rothblatt | CEO | Sell | 1,293 | $109.87 | $142,061.91 | 1,433 | |
| 6/30/2016 | Martine A Rothblatt | CEO | Sell | 1,308 | $105.10 | $137,470.80 | 1,548 | |
| 6/23/2016 | Martine A Rothblatt | CEO | Sell | 1,312 | $104.07 | $136,539.84 | 1,552 | |
| 6/16/2016 | Martine A Rothblatt | CEO | Sell | 1,308 | $105.18 | $137,575.44 | 1,548 | |
| 6/9/2016 | Martine A Rothblatt | CEO | Sell | 1,277 | $114.99 | $146,842.23 | 1,517 | |
| 6/8/2016 | Tommy G Thompson | Director | Sell | 2,000 | $115.62 | $231,240.00 | 2,000 | |
| 6/2/2016 | Martine A Rothblatt | CEO | Sell | 1,261 | $120.79 | $152,316.19 | 1,501 | |
| 6/2/2016 | Raymond Dwek | Director | Sell | 3,000 | $118.82 | $356,460.00 | 3,000 | |
| 5/26/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $117.57 | $652,160.79 | 5,787 | |
| 5/19/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $110.75 | $614,219.50 | 5,786 | |
| 5/12/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $109.02 | $604,733.94 | 5,787 | |
| 5/12/2016 | Raymond Dwek | Director | Sell | 3,000 | $110.00 | $330,000.00 | 3,000 | |
| 5/5/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $107.79 | $597,803.34 | 5,786 | |
| 4/28/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $106.81 | $592,475.07 | 5,787 | |
| 4/21/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $115.74 | $641,894.04 | 5,786 | |
| 4/14/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $114.32 | $634,133.04 | 5,787 | |
| 4/7/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $113.31 | $628,417.26 | 5,786 | |
| 3/24/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $110.80 | $614,496.80 | 5,786 | |
| 3/17/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $118.22 | $655,766.34 | 5,787 | |
| 3/10/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $123.41 | $684,431.86 | 5,786 | |
| 3/3/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $126.78 | $703,248.66 | 5,787 | |
| 2/25/2016 | Martine A Rothblatt | CEO | Sell | 5,546 | $122.45 | $679,107.70 | 5,786 | |
| 2/18/2016 | Martine A Rothblatt | CEO | Sell | 5,547 | $128.26 | $711,458.22 | 5,787 | |
| 2/11/2016 | Martine A. Rothblatt | CEO | Sell | 5,546 | $120.47 | $668,126.62 | 240 | |
| 2/4/2016 | Martine A. Rothblatt | CEO | Sell | 5,547 | $122.13 | $677,455.11 | 240 | |
| 2/4/2016 | Raymond Dwek | Director | Sell | 3,000 | $122.66 | $367,980.00 | | |
| 1/28/2016 | Martine A. Rothblatt | CEO | Sell | 5,546 | $124.00 | $687,704.00 | 240 | |
| 1/21/2016 | Martine A. Rothblatt | CEO | Sell | 5,547 | $127.00 | $704,469.00 | 240 | |
| 1/14/2016 | Martine A. Rothblatt | CEO | Sell | 5,546 | $135.94 | $753,923.24 | 240 | |
| 1/7/2016 | Martine A. Rothblatt | CEO | Sell | 5,547 | $145.84 | $808,974.48 | 240 | |
| 1/7/2016 | Raymond Dwek | Director | Sell | 3,000 | $143.75 | $431,250.00 | | |
| 12/24/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $159.58 | $885,030.68 | 240 | |
| 12/17/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $158.49 | $878,985.54 | 240 | |
| 12/10/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $154.49 | $856,801.54 | 240 | |
| 12/3/2015 | Martine A. Rothblatt | CEO | Sell | 5,546 | $154.49 | $856,801.54 | 240 | |
| 12/3/2015 | Raymond Dwek | Director | Sell | 3,000 | $157.22 | $471,660.00 | | |
| 11/27/2015 | Martine A. Rothblatt | CEO | Sell | 5,561 | $153.81 | $855,337.41 | 240 | |
| 11/19/2015 | Martine A. Rothblatt | CEO | Sell | 9,661 | $148.56 | $1,435,238.16 | 240 | |
| 11/12/2015 | Martine A. Rothblatt | CEO | Sell | 4,115 | $147.72 | $607,867.80 | 240 | |
| 11/5/2015 | Martine A. Rothblatt | CEO | Sell | 4,115 | $149.16 | $613,793.40 | 240 | |
| 11/5/2015 | Raymond Dwek | Director | Sell | 3,000 | $149.63 | $448,890.00 | | |
| 11/3/2015 | Richard Giltner | Director | Sell | 7,500 | $153.22 | $1,149,150.00 | | |
| 10/29/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $141.89 | $1,370,941.18 | 240 | |
| 10/28/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $136.58 | $301,978.38 | 240 | |
| 10/26/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $127.13 | $329,520.96 | 240 | |
| 10/22/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $122.40 | $1,182,628.80 | 240 | |
| 10/21/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $123.63 | $273,345.93 | 240 | |
| 10/19/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $126.71 | $328,432.32 | 240 | |
| 10/15/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $126.22 | $1,219,537.64 | 240 | |
| 10/14/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $123.53 | $273,124.83 | 240 | |
| 10/12/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $123.51 | $320,137.92 | 240 | |
| 10/8/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $122.48 | $1,183,401.76 | 240 | |
| 10/7/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $120.88 | $267,265.68 | 240 | |
| 10/5/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $126.88 | $328,872.96 | 240 | |
| 10/1/2015 | Martine A. Rothblatt | CEO | Sell | 6,326 | $131.11 | $829,401.86 | 240 | |
| 10/1/2015 | Paul A. Mahon | EVP | Sell | 6,000 | $129.38 | $776,280.00 | 35,054 | |
| 10/1/2015 | Raymond Dwek | Director | Sell | 3,000 | $131.32 | $393,960.00 | | |
| 9/29/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $134.25 | $347,976.00 | 240 | |
| 9/29/2015 | Tommy G. Thompson | Director | Sell | 5,000 | $139.19 | $695,950.00 | | |
| 9/24/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $139.26 | $1,345,530.12 | 240 | |
| 9/23/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $142.05 | $314,072.55 | 240 | |
| 9/21/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $150.81 | $390,899.52 | 240 | |
| 9/17/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $152.02 | $1,468,817.24 | 240 | |
| 9/16/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $151.93 | $335,917.23 | 240 | |
| 9/14/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $153.08 | $396,783.36 | 240 | |
| 9/10/2015 | Martine A. Rothblatt | CEO | Sell | 4,115 | $152.95 | $629,389.25 | 240 | |
| 9/9/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $152.77 | $337,774.47 | 240 | |
| 9/8/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $152.80 | $396,057.60 | 240 | |
| 9/3/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $153.67 | $1,484,759.54 | 240 | |
| 9/3/2015 | Raymond Dwek | Director | Sell | 3,000 | $155.54 | $466,620.00 | | |
| 9/2/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $151.12 | $334,126.32 | 240 | |
| 8/31/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $153.50 | $397,872.00 | 240 | |
| 8/27/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $160.37 | $1,549,494.94 | 240 | |
| 8/26/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $155.47 | $343,744.17 | 240 | |
| 8/24/2015 | Martine A. Rothblatt | CEO | Sell | 2,592 | $155.36 | $402,693.12 | 240 | |
| 8/20/2015 | Martine A. Rothblatt | CEO | Sell | 9,662 | $166.58 | $1,609,495.96 | 240 | |
| 8/19/2015 | Martine A. Rothblatt | CEO | Sell | 2,211 | $167.13 | $369,524.43 | 240 | |
| 8/17/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $166.61 | $431,853.12 | | |
| 8/13/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $165.05 | $1,594,713.10 | | |
| 7/27/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $166.38 | $431,256.96 | | |
| 7/23/2015 | Martine A Rothblatt | CEO | Sell | 4,115 | $176.38 | $725,803.70 | | |
| 7/22/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $174.55 | $385,930.05 | | |
| 7/20/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.92 | $461,168.64 | | |
| 7/16/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $175.51 | $1,695,777.62 | | |
| 7/15/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $176.77 | $390,838.47 | | |
| 7/13/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $172.42 | $446,912.64 | | |
| 7/9/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $168.04 | $1,623,602.48 | | |
| 7/8/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $167.13 | $369,524.43 | | |
| 7/6/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $170.66 | $442,350.72 | | |
| 7/2/2015 | Martine A Rothblatt | CEO | Sell | 6,326 | $170.69 | $1,079,784.94 | | |
| 7/2/2015 | Raymond Dwek | Director | Sell | 3,000 | $171.59 | $514,770.00 | | |
| 6/29/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $172.86 | $448,053.12 | | |
| 6/25/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $176.91 | $1,709,304.42 | | |
| 6/24/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $179.68 | $397,272.48 | | |
| 6/22/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $188.64 | $488,954.88 | | |
| 6/18/2015 | Louis W Sullivan | Director | Sell | 15,000 | $185.60 | $2,784,000.00 | | |
| 6/18/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $185.72 | $1,794,426.64 | | |
| 6/17/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $185.25 | $409,587.75 | | |
| 6/15/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $185.15 | $479,908.80 | | |
| 6/11/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $183.76 | $1,775,489.12 | | |
| 6/10/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $180.87 | $399,903.57 | | |
| 6/8/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $181.34 | $470,033.28 | | |
| 6/4/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $181.94 | $1,757,904.28 | | |
| 6/4/2015 | Raymond Dwek | Director | Sell | 3,000 | $181.36 | $544,080.00 | | |
| 6/3/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $184.49 | $407,907.39 | | |
| 6/1/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $182.66 | $473,454.72 | | |
| 5/28/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $180.88 | $1,747,662.56 | | |
| 5/27/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $184.39 | $407,686.29 | | |
| 5/26/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $182.64 | $473,402.88 | | |
| 5/21/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $182.44 | $1,762,735.28 | | |
| 5/21/2015 | Tommy G Thompson | Director | Sell | 1,500 | $182.04 | $273,060.00 | | |
| 5/20/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $182.80 | $404,170.80 | | |
| 5/18/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.79 | $460,831.68 | | |
| 5/14/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $174.07 | $1,681,864.34 | | |
| 5/13/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $175.41 | $387,831.51 | | |
| 5/11/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $179.55 | $465,393.60 | | |
| 5/7/2015 | Christopher Causey | Director | Sell | 1,500 | $167.94 | $251,910.00 | | |
| 5/7/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $169.86 | $1,641,187.32 | | |
| 5/6/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $169.22 | $374,145.42 | | |
| 5/4/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $169.81 | $440,147.52 | | |
| 5/1/2015 | Raymond Dwek | Director | Sell | 3,000 | $159.58 | $478,740.00 | | |
| 4/30/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $162.36 | $1,568,722.32 | | |
| 4/29/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $164.29 | $363,245.19 | | |
| 4/28/2015 | Roger Jeffs | CEO | Sell | 5,000 | $163.31 | $816,550.00 | | |
| 4/27/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.62 | $460,391.04 | | |
| 4/23/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $187.35 | $1,810,175.70 | | |
| 4/22/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $187.49 | $414,540.39 | | |
| 4/21/2015 | Roger Jeffs | CEO | Sell | 10,000 | $187.86 | $1,878,600.00 | | |
| 4/20/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $184.86 | $479,157.12 | | |
| 4/16/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $187.01 | $2,220,369.73 | | |
| 4/16/2015 | Paul A Mahon | EVP | Sell | 6,000 | $187.91 | $1,127,460.00 | | |
| 4/14/2015 | David Zaccardelli | COO | Sell | 3,250 | $185.82 | $603,915.00 | | |
| 4/14/2015 | Roger Jeffs | CEO | Sell | 10,000 | $185.82 | $1,858,200.00 | | |
| 4/13/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $187.86 | $486,933.12 | | |
| 4/9/2015 | David Zaccardelli | COO | Sell | 4,000 | $184.84 | $739,360.00 | | |
| 4/9/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $183.09 | $1,769,015.58 | | |
| 4/8/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $181.91 | $402,203.01 | | |
| 4/7/2015 | David Zaccardelli | COO | Sell | 4,000 | $179.34 | $717,360.00 | | |
| 4/7/2015 | Roger Jeffs | CEO | Sell | 10,000 | $179.34 | $1,793,400.00 | | |
| 4/6/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $176.20 | $456,710.40 | | |
| 4/2/2015 | David Zaccardelli | COO | Sell | 4,000 | $174.73 | $698,920.00 | | |
| 4/2/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $173.43 | $2,059,134.39 | | |
| 4/2/2015 | Paul A Mahon | EVP | Sell | 6,000 | $174.73 | $1,048,380.00 | | |
| 4/2/2015 | Raymond Dwek | Director | Sell | 3,000 | $175.49 | $526,470.00 | | |
| 3/30/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.22 | $459,354.24 | | |
| 3/26/2015 | David Zaccardelli | COO | Sell | 4,000 | $167.52 | $670,080.00 | | |
| 3/26/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $167.03 | $1,613,843.86 | | |
| 3/25/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $173.67 | $383,984.37 | | |
| 3/24/2015 | David Zaccardelli | COO | Sell | 4,500 | $179.51 | $807,795.00 | | |
| 3/23/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $177.76 | $460,753.92 | | |
| 3/19/2015 | Paul A Mahon | EVP | Sell | 6,000 | $175.82 | $1,054,920.00 | | |
| 3/18/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $174.64 | $386,129.04 | | |
| 3/17/2015 | David Zaccardelli | COO | Sell | 4,000 | $177.34 | $709,360.00 | | |
| 3/16/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $170.97 | $443,154.24 | | |
| 3/12/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $162.94 | $1,934,586.62 | | |
| 3/10/2015 | Roger Jeffs | CEO | Sell | 18,750 | $143.68 | $2,694,000.00 | | |
| 3/9/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $160.51 | $416,041.92 | | |
| 3/5/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $159.75 | $1,543,504.50 | | |
| 3/5/2015 | Raymond Dwek | Director | Sell | 3,000 | $157.59 | $472,770.00 | | |
| 3/4/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $157.63 | $348,519.93 | | |
| 3/3/2015 | Roger Jeffs | CEO | Sell | 10,000 | $157.74 | $1,577,400.00 | | |
| 3/2/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $155.32 | $402,589.44 | | |
| 2/27/2015 | Ray Kurzweil | Director | Sell | 15,000 | $155.05 | $2,325,750.00 | | |
| 2/26/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $155.23 | $1,499,832.26 | | |
| 2/25/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $159.35 | $352,322.85 | | |
| 2/24/2015 | David Zaccardelli | COO | Sell | 1,458 | $155.16 | $226,223.28 | | |
| 2/24/2015 | Roger Jeffs | CEO | Sell | 10,000 | $155.16 | $1,551,600.00 | | |
| 2/23/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $156.08 | $404,559.36 | | |
| 2/19/2015 | John Maxim Ferrari | CFO | Sell | 10,000 | $155.72 | $1,557,200.00 | | |
| 2/19/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $155.99 | $1,507,175.38 | | |
| 2/19/2015 | Paul A Mahon | EVP | Sell | 6,000 | $155.72 | $934,320.00 | | |
| 2/17/2015 | David Zaccardelli | COO | Sell | 4,000 | $155.14 | $620,560.00 | | |
| 2/17/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $152.28 | $394,709.76 | | |
| 2/12/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $146.01 | $1,410,748.62 | | |
| 2/11/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $147.29 | $325,658.19 | | |
| 2/10/2015 | David Zaccardelli | COO | Sell | 4,000 | $146.68 | $586,720.00 | | |
| 2/10/2015 | Roger Jeffs | CEO | Sell | 10,000 | $146.68 | $1,466,800.00 | | |
| 2/9/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $143.32 | $371,485.44 | | |
| 2/5/2015 | John Maxim Ferrari | CFO | Sell | 10,000 | $141.92 | $1,419,200.00 | | |
| 2/5/2015 | Martine A Rothblatt | CEO | Sell | 11,773 | $141.07 | $1,660,817.11 | | |
| 2/5/2015 | Paul A Mahon | EVP | Sell | 6,000 | $141.92 | $851,520.00 | | |
| 2/5/2015 | Raymond Dwek | Director | Sell | 3,000 | $140.41 | $421,230.00 | | |
| 2/3/2015 | David Zaccardelli | COO | Sell | 4,000 | $141.99 | $567,960.00 | | |
| 2/3/2015 | Roger Jeffs | CEO | Sell | 10,000 | $141.99 | $1,419,900.00 | | |
| 1/29/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $143.29 | $1,384,467.98 | | |
| 1/28/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $145.49 | $321,678.39 | | |
| 1/27/2015 | David Zaccardelli | COO | Sell | 4,000 | $147.19 | $588,760.00 | | |
| 1/27/2015 | Roger Jeffs | CEO | Sell | 10,000 | $147.19 | $1,471,900.00 | | |
| 1/26/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $145.89 | $378,146.88 | | |
| 1/22/2015 | Martine A Rothblatt | CEO | Sell | 11,873 | $146.76 | $1,742,481.48 | | |
| 1/20/2015 | David Zaccardelli | COO | Sell | 4,000 | $146.48 | $585,920.00 | | |
| 1/20/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $145.06 | $375,995.52 | | |
| 1/15/2015 | John Maxim Ferrari | CFO | Sell | 22,500 | $137.84 | $3,101,400.00 | | |
| 1/15/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $137.51 | $1,328,621.62 | | |
| 1/15/2015 | Paul A Mahon | EVP | Sell | 6,000 | $137.84 | $827,040.00 | | |
| 1/14/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $135.18 | $298,882.98 | | |
| 1/13/2015 | David Zaccardelli | COO | Sell | 3,000 | $134.71 | $404,130.00 | | |
| 1/13/2015 | Roger Jeffs | CEO | Sell | 10,000 | $134.71 | $1,347,100.00 | | |
| 1/12/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.00 | $342,144.00 | | |
| 1/8/2015 | Christopher Patusky | Director | Sell | 5,000 | $128.13 | $640,650.00 | | |
| 1/8/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $128.31 | $1,239,731.22 | | |
| 1/7/2015 | Martine A Rothblatt | CEO | Sell | 2,211 | $126.04 | $278,674.44 | | |
| 1/6/2015 | David Zaccardelli | COO | Sell | 3,000 | $124.93 | $374,790.00 | | |
| 1/6/2015 | Roger Jeffs | CEO | Sell | 7,500 | $124.93 | $936,975.00 | | |
| 1/5/2015 | Martine A Rothblatt | CEO | Sell | 2,592 | $126.88 | $328,872.96 | | |
| 1/2/2015 | Christopher Causey | Director | Sell | 3,000 | $129.25 | $387,750.00 | | |
| 1/2/2015 | Martine A Rothblatt | CEO | Sell | 9,662 | $126.53 | $1,222,532.86 | | |
| 1/2/2015 | Paul A Mahon | EVP | Sell | 6,000 | $127.73 | $766,380.00 | | |
| 12/31/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $131.35 | $290,414.85 | | |
| 12/30/2014 | Roger Jeffs | CEO | Sell | 10,000 | $130.80 | $1,308,000.00 | | |
| 12/29/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $131.75 | $341,496.00 | | |
| 12/26/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $131.85 | $1,273,934.70 | | |
| 12/24/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $130.35 | $288,203.85 | | |
| 12/23/2014 | Roger Jeffs | COO | Sell | 10,000 | $127.82 | $1,278,200.00 | | |
| 12/22/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $133.45 | $345,902.40 | | |
| 12/19/2014 | Christopher Causey | Director | Sell | 1,500 | $131.47 | $197,205.00 | | |
| 12/18/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $131.11 | $1,311,100.00 | | |
| 12/18/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $129.06 | $1,246,977.72 | | |
| 12/18/2014 | Paul A Mahon | EVP | Sell | 10,750 | $130.03 | $1,397,822.50 | | |
| 12/17/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $126.04 | $278,674.44 | | |
| 12/15/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $129.75 | $336,312.00 | | |
| 12/11/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $130.98 | $1,265,528.76 | | |
| 12/10/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $132.77 | $293,554.47 | | |
| 12/9/2014 | Roger Jeffs | COO | Sell | 10,000 | $134.80 | $1,348,000.00 | | |
| 12/8/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.34 | $343,025.28 | | |
| 12/4/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $129.05 | $1,290,500.00 | | |
| 12/4/2014 | Martine A Rothblatt | CEO | Sell | 11,873 | $131.32 | $1,559,162.36 | | |
| 12/4/2014 | Paul A Mahon | EVP | Sell | 11,000 | $129.92 | $1,429,120.00 | | |
| 12/4/2014 | Raymond Dwek | Director | Sell | 3,000 | $131.58 | $394,740.00 | | |
| 12/2/2014 | Roger Jeffs | COO | Sell | 10,000 | $133.63 | $1,336,300.00 | | |
| 12/1/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.92 | $344,528.64 | | |
| 11/28/2014 | Martine A Rothblatt | CEO | Sell | 11,873 | $132.77 | $1,576,378.21 | | |
| 11/25/2014 | Roger Jeffs | COO | Sell | 10,000 | $131.30 | $1,313,000.00 | | |
| 11/24/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $130.72 | $338,826.24 | | |
| 11/21/2014 | Roger Jeffs | COO | Sell | 10,000 | $130.15 | $1,301,500.00 | | |
| 11/20/2014 | Christopher Causey | Director | Sell | 1,500 | $127.20 | $190,800.00 | | |
| 11/20/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $129.22 | $1,292,200.00 | | |
| 11/20/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $128.86 | $1,245,045.32 | | |
| 11/20/2014 | Paul A Mahon | EVP | Sell | 11,000 | $129.02 | $1,419,220.00 | | |
| 11/19/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $128.69 | $284,533.59 | | |
| 11/18/2014 | Roger Jeffs | COO | Sell | 10,000 | $128.21 | $1,282,100.00 | | |
| 11/17/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $125.65 | $325,684.80 | | |
| 11/13/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $124.79 | $1,205,720.98 | | |
| 11/12/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $122.88 | $271,687.68 | | |
| 11/10/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $125.14 | $324,362.88 | | |
| 11/7/2014 | Christopher Patusky | Director | Sell | 5,000 | $124.49 | $622,450.00 | | |
| 11/7/2014 | Roger Jeffs | COO | Sell | 10,000 | $124.46 | $1,244,600.00 | | |
| 11/6/2014 | Christopher Causey | Director | Sell | 1,500 | $122.89 | $184,335.00 | | |
| 11/6/2014 | Martine A Rothblatt | CEO | Sell | 4,115 | $125.33 | $515,732.95 | | |
| 11/6/2014 | Paul A Mahon | EVP | Sell | 5,000 | $125.02 | $625,100.00 | | |
| 11/5/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $124.31 | $274,849.41 | | |
| 11/3/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $127.49 | $330,454.08 | | |
| 10/30/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $130.42 | $1,260,118.04 | | |
| 10/29/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $131.10 | $289,862.10 | | |
| 10/27/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $132.16 | $342,558.72 | | |
| 10/23/2014 | Martine A Rothblatt | CEO | Sell | 11,873 | $129.97 | $1,543,133.81 | | |
| 10/23/2014 | Paul A Mahon | EVP | Sell | 11,000 | $127.04 | $1,397,440.00 | | |
| 10/13/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $124.31 | $322,211.52 | | |
| 10/9/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $129.97 | $1,255,770.14 | | |
| 10/9/2014 | Paul A Mahon | EVP | Sell | 5,000 | $130.59 | $652,950.00 | | |
| 10/8/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $131.50 | $290,746.50 | | |
| 10/7/2014 | Roger Jeffs | COO | Sell | 35,000 | $130.14 | $4,554,900.00 | | |
| 10/6/2014 | Martine A Rothblatt | CEO | Sell | 2,592 | $129.32 | $335,197.44 | | |
| 10/3/2014 | Roger Jeffs | COO | Sell | 10,000 | $129.79 | $1,297,900.00 | | |
| 10/2/2014 | Christopher Causey | Director | Sell | 1,500 | $130.65 | $195,975.00 | | |
| 10/2/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $129.46 | $1,294,600.00 | | |
| 10/2/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $127.72 | $1,234,030.64 | | |
| 10/2/2014 | Paul A Mahon | EVP | Sell | 6,000 | $129.46 | $776,760.00 | | |
| 10/1/2014 | Martine A Rothblatt | CEO | Sell | 2,211 | $127.40 | $281,681.40 | | |
| 9/30/2014 | Roger Jeffs | COO | Sell | 20,000 | $128.65 | $2,573,000.00 | | |
| 9/25/2014 | Martine A Rothblatt | CEO | Sell | 5,547 | $134.26 | $744,740.22 | | |
| 9/25/2014 | Paul A Mahon | EVP | Sell | 5,000 | $133.77 | $668,850.00 | | |
| 9/25/2014 | Richard Giltner | Director | Sell | 20,000 | $134.94 | $2,698,800.00 | | |
| 9/23/2014 | Roger Jeffs | COO | Sell | 50,000 | $131.02 | $6,551,000.00 | | |
| 9/19/2014 | Roger Jeffs | COO | Sell | 10,000 | $129.60 | $1,296,000.00 | | |
| 9/18/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $130.93 | $1,309,300.00 | | |
| 9/18/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $127.35 | $1,230,455.70 | | |
| 9/18/2014 | Paul A Mahon | EVP | Sell | 6,000 | $130.93 | $785,580.00 | | |
| 9/17/2014 | Roger Jeffs | COO | Sell | 20,000 | $127.01 | $2,540,200.00 | | |
| 9/15/2014 | Martine A Rothblatt | CEO | Sell | 50,000 | $124.52 | $6,226,000.00 | | |
| 9/11/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $120.79 | $1,167,072.98 | | |
| 9/11/2014 | Paul A Mahon | EVP | Sell | 5,000 | $120.70 | $603,500.00 | | |
| 9/10/2014 | Martine A Rothblatt | CEO | Sell | 50,000 | $120.01 | $6,000,500.00 | | |
| 9/10/2014 | Richard Giltner | Director | Sell | 20,000 | $119.95 | $2,399,000.00 | | |
| 9/5/2014 | Roger Jeffs | COO | Sell | 10,000 | $111.29 | $1,112,900.00 | | |
| 9/4/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $112.38 | $1,123,800.00 | | |
| 9/4/2014 | Martine A Rothblatt | CEO | Sell | 9,662 | $112.87 | $1,090,549.94 | | |
| 9/4/2014 | Paul A Mahon | EVP | Sell | 6,000 | $112.38 | $674,280.00 | | |
| 9/4/2014 | Raymond Dwek | Director | Sell | 3,000 | $113.40 | $340,200.00 | | |
| 8/28/2014 | Martine A Rothblatt | CEO | Sell | 7,014 | $92.46 | $648,514.44 | | |
| 8/28/2014 | Paul A Mahon | EVP | Sell | 5,000 | $92.07 | $460,350.00 | | |
| 8/21/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $93.75 | $937,500.00 | | |
| 8/21/2014 | Martine A Rothblatt | CEO | Sell | 9,640 | $93.13 | $897,773.20 | | |
| 8/15/2014 | Christopher Causey | Director | Sell | 1,500 | $91.14 | $136,710.00 | | |
| 8/14/2014 | Martine A Rothblatt | CEO | Sell | 4,115 | $88.39 | $363,724.85 | | |
| 8/14/2014 | Paul A Mahon | EVP | Sell | 10,000 | $88.41 | $884,100.00 | | |
| 8/7/2014 | Christopher Patusky | Director | Sell | 5,000 | $88.23 | $441,150.00 | | |
| 8/7/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $86.44 | $864,400.00 | | |
| 8/7/2014 | Martine A Rothblatt | CEO | Sell | 4,115 | $88.40 | $363,766.00 | | |
| 8/1/2014 | Raymond Dwek | Director | Sell | 3,000 | $89.52 | $268,560.00 | | |
| 8/1/2014 | Roger Jeffs | COO | Sell | 10,000 | $89.88 | $898,800.00 | | |
| 7/31/2014 | Martine A Rothblatt | CEO | Sell | 3,933 | $90.95 | $357,706.35 | | |
| 7/29/2014 | Roger Jeffs | COO | Sell | 50,000 | $96.25 | $4,812,500.00 | | |
| 7/25/2014 | Roger Jeffs | COO | Sell | 10,000 | $91.54 | $915,400.00 | | |
| 7/24/2014 | Martine A Rothblatt | CEO | Sell | 9,228 | $93.15 | $859,588.20 | | |
| 7/17/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $89.74 | $897,400.00 | | |
| 7/17/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $90.87 | $348,304.71 | | |
| 7/11/2014 | Roger Jeffs | COO | Sell | 10,000 | $93.06 | $930,600.00 | | |
| 7/10/2014 | Martine A Rothblatt | CEO | Sell | 9,187 | $92.33 | $848,235.71 | | |
| 7/3/2014 | Christopher Causey | Director | Sell | 1,500 | $91.62 | $137,430.00 | | |
| 7/3/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $90.58 | $905,800.00 | | |
| 7/3/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $91.37 | $350,221.21 | | |
| 6/26/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $87.23 | $334,352.59 | | |
| 6/20/2014 | Roger Jeffs | COO | Sell | 10,000 | $87.00 | $870,000.00 | | |
| 6/19/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $87.02 | $870,200.00 | | |
| 6/19/2014 | Martine A Rothblatt | CEO | Sell | 3,833 | $85.68 | $328,411.44 | | |
| 6/19/2014 | Paul A Mahon | EVP | Sell | 2,000 | $85.67 | $171,340.00 | | |
| 6/12/2014 | Martine A Rothblatt | CEO | Sell | 9,066 | $98.22 | $890,462.52 | | |
| 6/10/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.29 | $962,900.00 | | |
| 6/9/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.32 | $963,200.00 | | |
| 6/5/2014 | Christopher Causey | Director | Sell | 1,500 | $96.48 | $144,720.00 | | |
| 6/5/2014 | Martine A Rothblatt | CEO | Sell | 9,066 | $96.46 | $874,506.36 | | |
| 6/5/2014 | Paul A Mahon | EVP | Sell | 6,000 | $96.50 | $579,000.00 | | |
| 6/3/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.00 | $950,000.00 | | |
| 5/29/2014 | Martine A Rothblatt | CEO | Sell | 9,066 | $95.27 | $863,717.82 | | |
| 5/27/2014 | Roger Jeffs | COO | Sell | 10,000 | $99.14 | $991,400.00 | | |
| 5/22/2014 | Louis Sullivan | Director | Sell | 30,000 | $101.46 | $3,043,800.00 | | |
| 5/22/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $101.35 | $918,839.10 | 140 | |
| 5/20/2014 | Roger Jeffs | COO | Sell | 10,000 | $99.91 | $999,100.00 | 1,234 | |
| 5/16/2014 | Roger Jeffs | COO | Sell | 10,000 | $100.00 | $1,000,000.00 | 1,234 | |
| 5/15/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $101.49 | $1,014,900.00 | 407 | |
| 5/15/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $100.88 | $914,578.08 | 140 | |
| 5/15/2014 | Paul Mahon | EVP | Sell | 6,000 | $100.86 | $605,160.00 | 34,832 | |
| 5/13/2014 | Roger Jeffs | COO | Sell | 10,000 | $105.53 | $1,055,300.00 | 1,234 | |
| 5/8/2014 | Christopher Patusky | Director | Sell | 5,000 | $107.17 | $535,850.00 | | |
| 5/8/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $107.83 | $977,586.78 | 140 | |
| 5/6/2014 | Roger Jeffs | COO | Sell | 10,000 | $106.50 | $1,065,000.00 | 1,234 | |
| 5/2/2014 | Roger Jeffs | COO | Sell | 10,000 | $102.00 | $1,020,000.00 | 1,234 | |
| 5/1/2014 | Christopher Causey | Director | Sell | 1,500 | $99.30 | $148,950.00 | 733 | |
| 5/1/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $102.20 | $1,022,000.00 | 407 | |
| 5/1/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $101.84 | $923,281.44 | 140 | |
| 5/1/2014 | Paul Mahon | EVP | Sell | 6,000 | $102.71 | $616,260.00 | 34,832 | |
| 4/29/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.00 | $950,000.00 | 1,234 | |
| 4/24/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $92.45 | $838,151.70 | 140 | |
| 4/22/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.00 | $960,000.00 | 1,234 | |
| 4/17/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $96.20 | $962,000.00 | 407 | |
| 4/17/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $98.48 | $892,819.68 | 140 | |
| 4/17/2014 | Paul Mahon | EVP | Sell | 6,000 | $98.37 | $590,220.00 | 34,832 | |
| 4/15/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.06 | $950,600.00 | 1,234 | |
| 4/10/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $96.18 | $871,967.88 | 140 | |
| 4/8/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.00 | $950,000.00 | 1,234 | |
| 4/4/2014 | Roger Jeffs | COO | Sell | 10,000 | $93.22 | $932,200.00 | 1,234 | |
| 4/3/2014 | Christopher Causey | Director | Sell | 1,500 | $95.67 | $143,505.00 | 733 | |
| 4/3/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $93.22 | $932,200.00 | 407 | |
| 4/3/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $93.74 | $849,846.84 | 140 | |
| 4/3/2014 | Paul Mahon | EVP | Sell | 6,000 | $93.10 | $558,600.00 | 34,832 | |
| 4/1/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.44 | $954,400.00 | 1,234 | |
| 3/27/2014 | Martine Rothblatt | CEO | Sell | 9,066 | $93.35 | $846,311.10 | 140 | |
| 3/25/2014 | Roger Jeffs | COO | Sell | 10,000 | $95.64 | $956,400.00 | 1,234 | |
| 3/21/2014 | Roger Jeffs | COO | Sell | 10,000 | $93.84 | $938,400.00 | 1,234 | |
| 3/20/2014 | Christopher Causey | Director | Sell | 1,500 | $96.04 | $144,060.00 | 733 | |
| 3/20/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $96.11 | $961,100.00 | 407 | |
| 3/20/2014 | Martine Rothblatt | CEO | Sell | 9,065 | $96.76 | $877,129.40 | 140 | |
| 3/20/2014 | Paul Mahon | EVP | Sell | 6,000 | $96.81 | $580,860.00 | 34,832 | |
| 3/18/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.51 | $965,100.00 | 1,234 | |
| 3/13/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $95.64 | $366,588.12 | 140 | |
| 3/7/2014 | Roger Jeffs | COO | Sell | 10,000 | $99.02 | $990,200.00 | 1,234 | |
| 3/6/2014 | Christopher Patusky | Director | Sell | 5,000 | $101.39 | $506,950.00 | | |
| 3/6/2014 | John Maxim Ferrari | CFO | Sell | 10,000 | $99.07 | $990,700.00 | 407 | |
| 3/6/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $102.77 | $393,917.41 | 140 | |
| 3/6/2014 | Paul Mahon | EVP | Sell | 6,000 | $101.93 | $611,580.00 | 34,832 | |
| 2/28/2014 | Ray Kurzweil | Director | Sell | 15,000 | $101.42 | $1,521,300.00 | | |
| 2/27/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $100.68 | $385,906.44 | 140 | |
| 2/21/2014 | Roger Jeffs | COO | Sell | 10,000 | $104.89 | $1,048,900.00 | 897 | |
| 2/20/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $103.91 | $398,287.03 | 140 | |
| 2/20/2014 | Paul Mahon | EVP | Sell | 6,000 | $104.63 | $627,780.00 | 34,490 | |
| 2/13/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $99.87 | $382,801.71 | 140 | |
| 2/7/2014 | Roger Jeffs | COO | Sell | 10,000 | $96.61 | $966,100.00 | 897 | |
| 2/6/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $97.26 | $372,797.58 | 140 | |
| 2/6/2014 | Paul Mahon | EVP | Sell | 6,000 | $97.41 | $584,460.00 | 34,490 | |
| 2/6/2014 | Raymond Dwek | Director | Sell | 3,000 | $97.33 | $291,990.00 | | |
| 1/30/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $106.25 | $407,256.25 | 140 | |
| 1/23/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $111.78 | $428,452.74 | 140 | |
| 1/17/2014 | Roger Jeffs | COO | Sell | 10,000 | $113.03 | $1,130,300.00 | 897 | |
| 1/16/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $111.21 | $426,267.93 | 140 | |
| 1/16/2014 | Paul Mahon | EVP | Sell | 6,000 | $111.98 | $671,880.00 | 34,490 | |
| 1/9/2014 | Christopher Patusky | Director | Sell | 5,000 | $110.00 | $550,000.00 | | |
| 1/9/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $108.35 | $415,305.55 | 140 | |
| 1/3/2014 | Roger Jeffs | COO | Sell | 10,000 | $110.72 | $1,107,200.00 | 897 | |
| 1/2/2014 | Martine Rothblatt | CEO | Sell | 3,833 | $111.54 | $427,532.82 | 140 | |
| 1/2/2014 | Paul Mahon | EVP | Sell | 6,000 | $110.78 | $664,680.00 | 34,490 | |
| 1/2/2014 | Raymond Dwek | Director | Sell | 3,000 | $111.41 | $334,230.00 | | |
| 12/31/2013 | Martine Rothblatt | CEO | Sell | 18,140 | $112.64 | $2,043,289.60 | 140 | |
| 12/30/2013 | Martine Rothblatt | CEO | Sell | 18,147 | $111.60 | $2,025,205.20 | 140 | |
| 12/27/2013 | Martine Rothblatt | CEO | Sell | 18,147 | $113.15 | $2,053,333.05 | 140 | |
| 12/26/2013 | Martine Rothblatt | CEO | Sell | 21,981 | $111.95 | $2,460,772.95 | 140 | |
| 12/24/2013 | Martine Rothblatt | CEO | Sell | 18,149 | $114.05 | $2,069,893.45 | 140 | |
| 12/23/2013 | Martine Rothblatt | CEO | Sell | 5,743 | $109.71 | $630,064.53 | 140 | |
| 12/20/2013 | Martine Rothblatt | CEO | Sell | 18,149 | $86.72 | $1,573,881.28 | 140 | |
| 12/20/2013 | Roger Jeffs | COO | Sell | 8,250 | $87.84 | $724,680.00 | 897 | |
| 12/19/2013 | Martine Rothblatt | CEO | Sell | 21,982 | $86.73 | $1,906,498.86 | 140 | |
| 12/19/2013 | Paul Mahon | EVP | Sell | 6,000 | $86.45 | $518,700.00 | 34,490 | |
| 12/18/2013 | Martine Rothblatt | CEO | Sell | 18,149 | $86.36 | $1,567,347.64 | 140 | |
| 12/17/2013 | Martine Rothblatt | CEO | Sell | 12,251 | $86.49 | $1,059,588.99 | 140 | |
| 12/6/2013 | Roger Jeffs | COO | Sell | 10,000 | $90.97 | $909,700.00 | 19,760 | |
| 12/5/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $89.79 | $344,165.07 | 140 | |
| 12/5/2013 | Paul Mahon | EVP | Sell | 6,000 | $89.18 | $535,080.00 | 34,490 | |
| 12/5/2013 | Raymond Dwek | Director | Sell | 3,000 | $90.13 | $270,390.00 | | |
| 11/21/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $92.49 | $354,514.17 | 140 | |
| 11/21/2013 | Paul Mahon | EVP | Sell | 6,000 | $92.47 | $554,820.00 | 34,490 | |
| 11/15/2013 | Roger Jeffs | COO | Sell | 10,000 | $94.00 | $940,000.00 | 19,760 | |
| 11/14/2013 | Christopher Patusky | Director | Sell | 5,500 | $91.65 | $504,075.00 | | |
| 11/14/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $91.60 | $351,102.80 | 140 | |
| 11/7/2013 | Christopher Patusky | Director | Sell | 3,500 | $90.51 | $316,785.00 | | |
| 11/7/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $89.47 | $342,938.51 | 140 | |
| 11/7/2013 | Paul Mahon | EVP | Sell | 6,000 | $89.60 | $537,600.00 | 34,490 | |
| 11/1/2013 | Raymond Dwek | Director | Sell | 3,000 | $89.18 | $267,540.00 | | |
| 11/1/2013 | Roger Jeffs | COO | Sell | 10,000 | $90.34 | $903,400.00 | | |
| 10/31/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $86.89 | $333,049.37 | | |
| 10/24/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $83.77 | $321,090.41 | | |
| 10/18/2013 | Roger Jeffs | COO | Sell | 10,000 | $82.47 | $824,700.00 | | |
| 10/17/2013 | John Maxim Ferrari | CFO | Sell | 2,750 | $82.01 | $225,527.50 | | |
| 10/17/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $81.84 | $313,692.72 | | |
| 10/17/2013 | Paul A Mahon | EVP | Sell | 6,000 | $81.79 | $490,740.00 | | |
| 10/10/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $82.58 | $316,529.14 | 140 | |
| 10/4/2013 | Roger Jeffs | COO | Sell | 10,000 | $85.48 | $854,800.00 | | |
| 10/3/2013 | Christopher Causey | Director | Sell | 1,500 | $83.15 | $124,725.00 | | |
| 10/3/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $84.67 | $381,015.00 | | |
| 10/3/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $84.20 | $322,738.60 | | |
| 10/3/2013 | Paul A Mahon | EVP | Sell | 6,000 | $84.38 | $506,280.00 | | |
| 9/26/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $78.41 | $300,545.53 | 140 | |
| 9/20/2013 | Roger Jeffs | COO | Sell | 10,000 | $77.86 | $778,600.00 | 19,760 | |
| 9/19/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $78.67 | $354,015.00 | 407 | |
| 9/19/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $78.12 | $299,433.96 | 140 | |
| 9/19/2013 | Paul Mahon | EVP | Sell | 6,000 | $78.02 | $468,120.00 | 34,490 | |
| 9/12/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $76.98 | $295,064.34 | | |
| 9/6/2013 | Roger Jeffs | COO | Sell | 10,000 | $73.67 | $736,700.00 | | |
| 9/5/2013 | Christopher Causey | Director | Sell | 1,500 | $73.11 | $109,665.00 | | |
| 9/5/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $74.17 | $333,765.00 | | |
| 9/5/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $73.63 | $282,223.79 | | |
| 9/5/2013 | Paul A Mahon | EVP | Sell | 6,000 | $73.29 | $439,740.00 | | |
| 8/29/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $72.76 | $278,889.08 | 140 | |
| 8/22/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $72.06 | $276,205.98 | 140 | |
| 8/16/2013 | Roger Jeffs | COO | Sell | 10,000 | $71.21 | $712,100.00 | 19,760 | |
| 8/15/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $71.14 | $320,130.00 | | |
| 8/15/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $71.58 | $274,366.14 | 140 | |
| 8/15/2013 | Paul Mahon | EVP | Sell | 6,000 | $71.34 | $428,040.00 | 34,490 | |
| 8/8/2013 | Martine Rothblatt | CEO | Sell | 3,833 | $73.11 | $280,230.63 | 140 | |
| 8/2/2013 | Roger Jeffs | COO | Sell | 10,000 | $76.69 | $766,900.00 | | |
| 8/1/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $75.87 | $341,415.00 | | |
| 8/1/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $75.97 | $291,193.01 | | |
| 8/1/2013 | Paul A Mahon | EVP | Sell | 6,000 | $75.91 | $455,460.00 | | |
| 8/1/2013 | Raymond Dwek | Director | Sell | 3,000 | $75.94 | $227,820.00 | | |
| 7/31/2013 | R Paul Gray | Director | Sell | 7,500 | $74.93 | $561,975.00 | | |
| 7/25/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $71.45 | $273,867.85 | | |
| 7/19/2013 | Roger Jeffs | COO | Sell | 10,000 | $70.00 | $700,000.00 | | |
| 7/18/2013 | John Maxim Ferrari | CFO | Sell | 9,000 | $69.85 | $628,650.00 | | |
| 7/18/2013 | Martine A Rothblatt | CEO | Sell | 3,833 | $68.96 | $264,323.68 | | |
| 7/18/2013 | Paul A Mahon | EVP | Sell | 6,000 | $69.15 | $414,900.00 | | |
| 7/11/2013 | Martine A Rothblatt | CEO | Sell | 3,837 | $67.94 | $260,685.78 | | |
| 7/5/2013 | Christopher Causey | Director | Sell | 1,500 | $66.33 | $99,495.00 | | |
| 7/5/2013 | Martine A Rothblatt | CEO | Sell | 3,863 | $67.28 | $259,902.64 | | |
| 7/5/2013 | Paul A Mahon | EVP | Sell | 6,000 | $67.04 | $402,240.00 | | |
| 7/5/2013 | Roger Jeffs | COO | Sell | 10,000 | $67.21 | $672,100.00 | | |
| 6/21/2013 | Roger Jeffs | COO | Sell | 10,000 | $63.34 | $633,400.00 | | |
| 6/20/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $63.22 | $284,490.00 | | |
| 6/20/2013 | Paul A Mahon | EVP | Sell | 6,000 | $63.29 | $379,740.00 | | |
| 6/7/2013 | Roger Jeffs | COO | Sell | 10,000 | $67.00 | $670,000.00 | | |
| 6/6/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $64.84 | $291,780.00 | | |
| 6/6/2013 | Paul A Mahon | EVP | Sell | 6,000 | $63.84 | $383,040.00 | | |
| 6/6/2013 | Raymond Dwek | Director | Sell | 3,000 | $63.77 | $191,310.00 | | |
| 5/17/2013 | Roger Jeffs | COO | Sell | 10,000 | $69.17 | $691,700.00 | | |
| 5/16/2013 | John Maxim Ferrari | CFO | Sell | 4,500 | $68.48 | $308,160.00 | | |
| 5/16/2013 | Paul A Mahon | EVP | Sell | 6,000 | $68.05 | $408,300.00 | | |
| 5/2/2013 | Paul A Mahon | EVP | Sell | 6,000 | $67.15 | $402,900.00 | | |
| 5/2/2013 | Raymond Dwek | Director | Sell | 3,000 | $66.75 | $200,250.00 | | |
| 4/11/2013 | Raymond Dwek | Director | Sell | 9,000 | $61.35 | $552,150.00 | | |
| 1/17/2013 | Paul A Mahon | EVP | Sell | 5,749 | $52.20 | $300,097.80 | | |
| 12/28/2012 | Martine A Rothblatt | CEO | Buy | 4,167 | $52.40 | $218,350.80 | | |
| 12/26/2012 | Martine A Rothblatt | CEO | Buy | 6,000 | $52.40 | $314,400.00 | | |
| 12/21/2012 | Martine A Rothblatt | CEO | Buy | 9,000 | $51.85 | $466,650.00 | | |
| 11/26/2012 | Christopher Causey | Director | Sell | 1,500 | $53.33 | $79,995.00 | | |
| 10/4/2012 | Christopher Causey | Director | Sell | 1,500 | $58.33 | $87,495.00 | | |
| 10/4/2012 | John Maxim Ferrari | CFO | Sell | 1,550 | $58.00 | $89,900.00 | | |
| 10/4/2012 | Paul A Mahon | EVP | Sell | 6,000 | $38.00 | $228,000.00 | | |
| 9/6/2012 | Christopher Causey | Director | Sell | 1,500 | $55.94 | $83,910.00 | | |
| 9/5/2012 | Christopher Patusky | Director | Sell | 2,000 | $55.47 | $110,940.00 | | |
(Data available from 1/1/2013 forward)
United Therapeutics (NASDAQ UTHR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | 3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now
finance.yahoo.com - May 27 at 8:12 AM |
 | United Therapeutics Co. (UTHR) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 24 at 5:37 PM |
| United Therapeutics (UTHR) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - May 16 at 3:45 PM |
| SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 15 at 8:04 AM |
| $349.25 Million in Sales Expected for United Therapeutics Co. (UTHR) This Quarter
www.americanbankingnews.com - May 15 at 4:02 AM |
| Zacks: Brokerages Expect United Therapeutics Co. (UTHR) to Announce $3.36 EPS
www.americanbankingnews.com - May 13 at 10:23 AM |
 | Analysts: Generic drugs won’t affect United Therapeutics ‘that much’
www.bizjournals.com - May 9 at 5:56 PM |
| Jazz Pharmaceuticals to settle U.S. probe for $57 million
finance.yahoo.com - May 9 at 8:01 AM |
| Analysts: Generics won’t affect United Therapeutics ‘that much’
finance.yahoo.com - May 9 at 8:01 AM |
| Md. biotech to be acquired by New Jersey pharmaceutical goliath
finance.yahoo.com - May 8 at 8:01 AM |
 | Report: Exploring Fundamental Drivers Behind Reliance Steel & Aluminum, Goldman Sachs BDC, IBERIABANK ...
globenewswire.com - May 6 at 8:00 PM |
| Report: Exploring Fundamental Drivers Behind Reliance Steel & Aluminum, Goldman Sachs BDC, IBERIABANK, Federal Signal, United Therapeutics, and LifePoint Health — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - May 4 at 8:04 AM |
| United Therapeutics (UTHR) Price Target Lowered to $104.00 at Credit Suisse Group
www.americanbankingnews.com - May 4 at 12:17 AM |
| Barclays Trims United Therapeutics (UTHR) Target Price to $95.00
www.americanbankingnews.com - May 4 at 12:17 AM |
 | United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q
www.zacks.com - May 3 at 5:38 PM |
| Here's how much more money Greater Washington CEOs make than their employees
finance.yahoo.com - May 3 at 8:00 AM |
| Edited Transcript of UTHR earnings conference call or presentation 2-May-18 1:00pm GMT
finance.yahoo.com - May 3 at 8:00 AM |
 | United Therapeutics beats by $0.25, misses on revenue
seekingalpha.com - May 2 at 5:50 PM |
| United Therapeutics (UTHR) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 5:50 PM |
| United Therapeutics (UTHR) Releases Earnings Results, Beats Estimates By $1.95 EPS
www.americanbankingnews.com - May 2 at 12:02 PM |
| United Therapeutics Q1 top line up 5%; earnings up 37%
seekingalpha.com - May 2 at 8:06 AM |
| Blog Exposure - United Therapeutics Acquired SteadyMed for Approximately $216 Million
finance.yahoo.com - May 2 at 8:06 AM |
| United Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 8:06 AM |
| United Therapeutics Corporation Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 8:06 AM |
| Cardiome up 13% premarket on United Therapeutics' takeout of SteadyMed
seekingalpha.com - May 1 at 5:29 PM |
 | BRIEF-United Therapeutics To Acquire SteadyMed For $4.46 Per Share In Cash
www.reuters.com - May 1 at 5:29 PM |
 | Stock Review for Drug Makers Investors -- Endo, Ionis Pharma, Novo Nordisk ...
www.prnewswire.com - May 1 at 8:05 AM |
| United Therapeutics to acquire rival drugmaker
www.bizjournals.com - May 1 at 8:05 AM |
| United Therapeutics (UTHR) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - May 1 at 8:02 AM |
 | United Therapeutics (UTHR) to Acquire SteadyMed (STDY) for Up to $216M
www.streetinsider.com - April 30 at 5:26 PM |
| Taking out potential competition, drug maker says it will buy East Bay rival
finance.yahoo.com - April 30 at 5:26 PM |
| Stock Review for Drug Makers Investors -- Endo, Ionis Pharma, Novo Nordisk, and United Therapeutics
www.bizjournals.com - April 30 at 8:00 AM |
| SteadyMed up 64% premarket on acquisition by United Therapeutics for up to $216M
seekingalpha.com - April 30 at 8:00 AM |
| United Therapeutics Co. (UTHR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 29 at 5:41 PM |
| United Therapeutics' Martine Rothblatt saw a big pay jump in 2017
www.bizjournals.com - April 27 at 5:26 PM |
| BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln
www.reuters.com - April 27 at 8:05 AM |
| Zacks: Analysts Anticipate United Therapeutics Co. (UTHR) Will Announce Quarterly Sales of $384.73 Million
www.americanbankingnews.com - April 27 at 2:02 AM |
| Zacks: Brokerages Expect United Therapeutics Co. (UTHR) Will Announce Earnings of $4.23 Per Share
www.americanbankingnews.com - April 25 at 9:23 PM |
| United Therapeutics (UTHR) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 12:18 PM |
| United Therapeutics Corporation To Report First Quarter 2018 Financial Results Before The Market Opens On ...
www.prnewswire.com - April 25 at 8:01 AM |
| United Therapeutics Corporation To Report First Quarter 2018 Financial Results Before The Market Opens On Wednesday, May 2, 2018
finance.yahoo.com - April 24 at 8:04 AM |
 | Commit To Purchase United Therapeutics Corp At $100, Earn 12.5% Annualized Using Options
www.nasdaq.com - April 20 at 5:35 PM |
| United Therapeutics (UTHR) to Release Earnings on Tuesday
www.americanbankingnews.com - April 17 at 3:46 AM |
| United Therapeutics Co. (UTHR) CEO Martine A. Rothblatt Sells 21,513 Shares
www.americanbankingnews.com - April 11 at 4:15 PM |
| Zacks: Analysts Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $397.50 Million
www.americanbankingnews.com - April 10 at 2:01 AM |
| $3.64 EPS Expected for United Therapeutics Co. (UTHR) This Quarter
www.americanbankingnews.com - April 8 at 11:16 PM |
| Martine A. Rothblatt Sells 21,512 Shares of United Therapeutics Co. (UTHR) Stock
www.americanbankingnews.com - April 6 at 4:17 PM |
| United Therapeutics buys two D.C. buildings for $6.5M for 'potential future expansion'
www.bizjournals.com - April 5 at 5:31 PM |
| Cowen Reaffirms Hold Rating for United Therapeutics (UTHR)
www.americanbankingnews.com - April 4 at 5:52 PM |
| Insider Selling: United Therapeutics Co. (UTHR) CEO Sells 22,059 Shares of Stock
www.americanbankingnews.com - April 4 at 4:19 PM |
United Therapeutics (NASDAQ:UTHR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
United Therapeutics (NASDAQ:UTHR) Income Statement, Balance Sheet and Cash Flow Statement
United Therapeutics (NASDAQ UTHR) Stock Chart for Sunday, May, 27, 2018
Loading chart…
